Diabetes Mellitus, Experimental
"Diabetes Mellitus, Experimental" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.
| Descriptor ID |
D003921
|
| MeSH Number(s) |
C18.452.394.750.074 C19.246.240 E05.598.500.374
|
| Concept/Terms |
Streptozotocin Diabetes- Streptozotocin Diabetes
- Diabetes, Streptozotocin
- Streptozocin Diabetes
- Diabete, Streptozocin
- Diabetes, Streptozocin
- Streptozocin Diabete
|
Below are MeSH descriptors whose meaning is more general than "Diabetes Mellitus, Experimental".
Below are MeSH descriptors whose meaning is more specific than "Diabetes Mellitus, Experimental".
This graph shows the total number of publications written about "Diabetes Mellitus, Experimental" by people in this website by year, and whether "Diabetes Mellitus, Experimental" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 3 | 0 | 3 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 2 | 3 |
| 2002 | 5 | 2 | 7 |
| 2003 | 5 | 1 | 6 |
| 2004 | 1 | 2 | 3 |
| 2005 | 3 | 2 | 5 |
| 2006 | 5 | 3 | 8 |
| 2007 | 4 | 2 | 6 |
| 2008 | 2 | 3 | 5 |
| 2009 | 5 | 6 | 11 |
| 2010 | 6 | 1 | 7 |
| 2011 | 7 | 2 | 9 |
| 2012 | 6 | 3 | 9 |
| 2013 | 4 | 4 | 8 |
| 2014 | 3 | 2 | 5 |
| 2015 | 6 | 1 | 7 |
| 2016 | 4 | 5 | 9 |
| 2017 | 4 | 0 | 4 |
| 2018 | 4 | 0 | 4 |
| 2019 | 6 | 2 | 8 |
| 2021 | 3 | 2 | 5 |
| 2022 | 5 | 0 | 5 |
| 2023 | 3 | 0 | 3 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diabetes Mellitus, Experimental" by people in Profiles.
-
NDUFS4 regulates cristae remodeling in diabetic kidney disease. Nat Commun. 2024 Mar 04; 15(1):1965.
-
No NLRP3 inflammasome activity in kidney epithelial cells, not even when the NLRP3-A350V Muckle-Wells variant is expressed in podocytes of diabetic mice. Front Immunol. 2023; 14:1230050.
-
Secretogranin III Selectively Promotes Vascular Leakage in the Deep Vascular Plexus of Diabetic Retinopathy. Int J Mol Sci. 2023 Jun 23; 24(13).
-
Induction of Type 2 Diabetes in Mice to Understand Vascular Changes That Drive Diabetic Retinopathy. Methods Mol Biol. 2023; 2678:1-12.
-
Nanocurcumin combined with insulin alleviates diabetic kidney disease through P38/P53 signaling axis. J Control Release. 2023 01; 353:621-633.
-
Integrative transcriptome analysis reveals TEKT2 and PIAS2 involvement in diabetic nephropathy. FASEB J. 2022 11; 36(11):e22592.
-
Human Islet Amyloid Polypeptide (hIAPP) Protofibril-Specific Antibodies for Detection and Treatment of Type 2 Diabetes. Adv Sci (Weinh). 2022 12; 9(34):e2202342.
-
The proteasome activator REG? promotes diabetic endothelial impairment by inhibiting HMGA2-GLUT1 pathway. Transl Res. 2022 08; 246:33-48.
-
Diabetic Retinopathy: From Animal Models to Cellular Signaling. Int J Mol Sci. 2022 Jan 27; 23(3).
-
Tribbles Homolog 3 Mediates the Development and Progression of Diabetic Retinopathy. Diabetes. 2021 08; 70(8):1738-1753.